CXCR5/CXCL13 pathway, a key driver for migration of regulatory B10 cells, is defective in patients with rheumatoid arthritis.


Journal

Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501

Informations de publication

Date de publication:
05 05 2022
Historique:
received: 28 01 2021
revised: 23 06 2021
pubmed: 13 8 2021
medline: 10 5 2022
entrez: 12 8 2021
Statut: ppublish

Résumé

Chemokines (CKs) are key players of immune-cell homing and differentiation. CK receptors (CKRs) can be used to define T-cell functional subsets. We aimed to characterize the CKR profile of the regulatory B-cell subset B10+ cells and investigate the CKs involved in their migration and differentiation in healthy donors and patients with RA. RNA sequencing and cytometry were used to compare CKR expression between B10+ and B10neg cells. Migration of B10+ and B10neg cells and IL-10 secretion of B cells in response to recombinant CKs or synovial fluid (SF) were assessed. CXCR5 was expressed at a higher level on the B10+ cell surface as compared with other B cells (referred to as B10neg cells). In line with this, its ligand CXCL13 preferentially attracted B10+ cells over B10neg cells. Interestingly, synovial fluid from RA patients contained high levels of CXCL13 and induced strong and preferential migration of B10+ cells. Besides its role in attracting B10+ cells, CXCL13 also promoted IL-10 secretion by B cells. In RA patients, the level of CXCR5 on B-cell surface was reduced. The preferential migration of RA B10+ cells toward CXCL13-rich SF was lost and CXCL13 stimulation triggered less IL-10 secretion than in healthy donors. Our results identify that the CXCR5/CXCL13 axis is essential for B10+ cell biology but is defective in RA. Restoring the preferential migration of B10+ within the affected joints to better control inflammation may be part of the therapeutic approach for RA.

Identifiants

pubmed: 34382069
pii: 6348185
doi: 10.1093/rheumatology/keab639
doi:

Substances chimiques

CXCL13 protein, human 0
CXCR5 protein, human 0
Chemokine CXCL13 0
Receptors, CXCR5 0
Interleukin-10 130068-27-8

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2185-2196

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Claire Rempenault (C)

Rheumatology, CHU and University of Montpellier.

Julie Mielle (J)

IGMM, University of Montpellier, CNRS, Montpellier.

Kristina Schreiber (K)

Rheumatology, CHU and University of Montpellier.

Pierre Corbeau (P)

Immunology, CHU and University of Montpellier, Nîmes.
IGH, CNRS, Montpellier, France.

Laurence Macia (L)

Charles Perkins Centre, The University of Sydney, Sydney, Australia.

Bernard Combe (B)

Rheumatology, CHU and University of Montpellier.

Jacques Morel (J)

Rheumatology, CHU and University of Montpellier.

Claire Immediato Daien (CI)

Rheumatology, CHU and University of Montpellier.
IGMM, University of Montpellier, CNRS, Montpellier.

Rachel Audo (R)

Rheumatology, CHU and University of Montpellier.
IGMM, University of Montpellier, CNRS, Montpellier.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH